Antimicrobial peptides in oral medicine: From mechanisms to clinical translation
en-GBde-DEes-ESfr-FR

Antimicrobial peptides in oral medicine: From mechanisms to clinical translation

09/12/2025 TranSpread

Oral diseases, including dental caries, periodontitis, and oral cancer, affect approximately 3.5 billion people worldwide. Traditional treatments mainly rely on antibiotics, but the widespread emergence of bacterial resistance has significantly reduced their efficacy. Hence, the need for safe and effective alternative therapies remains.

Antimicrobial peptides (AMPs), key components of the innate immune system, are small-molecule polypeptides widely existing in nature. Unlike traditional antibiotics that target specific metabolic pathways, AMPs primarily act by physically destroying microbial cell membranes—a unique mechanism that minimizes the risk of inducing resistance. Additionally, AMPs possess multiple biological functions such as regulating immune responses, reducing inflammation, and promoting tissue repair, with high biocompatibility to human cells.

In a new study(doi: https://doi.org/10.1016/j.tdr.2025.100046) published in Translational Dental Research, a team of researchers from China reviewed AMP classification, antimicrobial mechanisms, and roles in treating oral diseases.

“In the treatment of dental caries, AMPs like Temporin-GHa derivatives, ZXR-2, and GH12 can inhibit the growth of cariogenic bacteria such as Streptococcus mutans, interfere with biofilm formation, and even promote tooth remineralization,” shares senior and co-corresponding author Qiang Feng. “For periodontitis, human-derived AMPs (e.g., α-defensins, β-defensins) and synthetic peptides (e.g., Nal-P-113) effectively kill periodontal pathogens, regulate inflammatory responses by inhibiting pro-inflammatory cytokine secretion, and enhance periodontal tissue regeneration.”

In oral cancer therapy, AMPs such as Piscidin-1 and LL-37 induce cancer cell death through membrane disruption and apoptotic pathways, while also modulating anti-tumor immune responses. “AMPs like P-113 and Nisin A have shown significant efficacy in treating oral candidiasis, and peptides such as IB-367 and Histatin-5 alleviate oral mucositis by inhibiting infection and promoting wound healing,” adds Feng.

Several AMPs have entered clinical trials, including C16G2 for dental caries, Nal-P-113 for periodontitis, and P-113 for oral candidiasis, demonstrating their clinical potential. Beyond direct therapy, AMPs are being developed into implant coatings to prevent peri-implant infections, oral dressings for sustained release, and combined with antibiotics or nanoparticles to enhance therapeutic effects. They also show promise as diagnostic markers for oral diseases by detecting changes in their expression levels.

However, clinical translation of AMPs faces challenges: oral enzymes, pH fluctuations, and high salt concentrations affect their stability; cationic and amphiphilic properties may lead to cytotoxicity and immunogenicity; and large-scale production is costly. “To address these, researchers have developed strategies such as chemical modification (e.g., N-acetylation, lipidation), nanocarrier delivery systems, sequence optimization with D-amino acids, and microbial/plant-based heterologous expression to improve stability, reduce toxicity, and lower production costs,” says Feng. “AMPs' multifunctional properties and low resistance potential make them a game-changer in oral medicine.”

The authors noted that future research should focus on clarifying their interaction mechanisms with oral microbiota and host cells, accelerating peptide screening through artificial intelligence, and developing tailored formulations for the oral microenvironment to promote clinical application.

###

References

DOI

10.1016/j.tdr.2025.100046

Original Source URL

https://doi.org/10.1016/j.tdr.2025.100046

Funding information

National Natural Science Foundation of China (82270980), Jinan Periodontitis Innovation Team
(2021GXRC021), Shandong Province Major Innovation Project (2021SFGC0502), Shandong Province Oral Microbiome Innovation Team (2020KJK001).

About Translational Dental Research (TDR)

Translational Dental Research (TDR) is the first specialized international journal dedicated to translational dental medicine. It aims to promote scientific research with clinical application and high translational value, and build a leading platform for advancing knowledge exchange among dental and clinical experts and scientists in basic medicine, science, engineering, humanities, and social sciences. TDR focuses on interdisciplinary research in the fields of stomatology, and science and engineering, including theoretical innovation, technological breakthroughs, research and development, and transformation achievements that drive advancements in dental science.

Paper title: Antimicrobial peptides in oral medicine: From mechanisms to clinical translation
Fichiers joints
  • Roles in oral disease treatment and applications in oral medicine of AMPs.
09/12/2025 TranSpread
Regions: North America, United States, Asia, China
Keywords: Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Témoignages

We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

Nous travaillons en étroite collaboration avec...


  • e
  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2025 by DNN Corp Terms Of Use Privacy Statement